University of Copenhagen

Scientists discovered a new weight loss drug, NK2R, similar to Ozempic but without muscle loss or nausea. NK2R targets the brain to reduce appetite and boosts calorie burning in muscles and fat. Researchers aim to start human trials within two years.

Scientists identified a new drug target, Neurokinin 2 Receptor (NK2R), that reduces appetite and increases calorie burning without nausea, potentially benefiting those with obesity and type 2 diabetes.

Researchers at the University of Copenhagen identified a new drug target, activating the neurokinin 2 receptor (NK2R), which reduces appetite, boosts calorie burning, and improves insulin sensitivity without side effects like nausea or muscle loss, potentially revolutionising obesity and type 2 diabetes treatment.

Researchers at the University of Copenhagen discovered a new drug candidate targeting Neurokinin 2 Receptor (NK2R) that lowers appetite and increases energy expenditure without nausea, potentially benefiting 400 million people with obesity and type 2 diabetes.

Scientists at the University of Copenhagen discovered a new weight loss drug target, NK2R, which reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or muscle loss. This could lead to new therapies for obesity and type 2 diabetes, benefiting millions globally.

A new weight loss drug targeting Neurokinin 2 Receptor (NK2R) shows promise in reducing appetite and increasing calorie expenditure without common side effects. This breakthrough, researched at the University of Copenhagen, could benefit those unresponsive to current GLP-1-based therapies. Meanwhile, apps like Srama's offer real-time caloric tracking, emphasizing personalized weight management through informed lifestyle choices.

New drug target, Neurokinin 2 Receptor (NK2R), could reduce appetite and burn calories without nausea, potentially benefiting millions with obesity and type 2 diabetes.

GLP-1 receptor agonists like Ozempic are effective for weight loss but not a long-term solution alone; physical activity is crucial for sustained benefits. Wearable technology can objectively assess physical activity and improve clinical trial outcomes, offering more precise evidence for obesity treatments.

European scientists developed an AI algorithm to interpret pig sounds, aiming to improve animal welfare by alerting farmers to negative emotions, potentially leading to better-informed consumer choices.

Novo Nordisk plans to use Denmark's first sovereign AI supercomputer, Gefion, powered by Nvidia technology for drug discovery. Nvidia CEO Jensen Huang and King Frederik X unveiled Gefion, equipped with 1,528 Nvidia GPUs, aiming to revolutionize digital biology. The Novo Nordisk Foundation owns Gefion, with Novo Nordisk among the first to utilize it for genomic foundation models and disease mutation analysis.